Yves Humblet

Department Of Medical Oncology Cliniques Universitaires St Luc And Institut De Recherche Clinique Et Experimentale
Brussels, BRU 1348, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Evolution of Metastases in Space and Time under Immune Selection.

Evolution of Metastases in Space and Time under Immune Selection.

Journal: Cell

Published: March 14, 2018

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Journal: Cancer discovery

Published: November 02, 2017

Phenotypic variation of an ALK-positive large-cell neuroendocrine lung carcinoma with carcinoid morphology during treatment with ALK inhibitors.

Phenotypic variation of an ALK-positive large-cell neuroendocrine lung carcinoma with carcinoid morphology during treatment with ALK inhibitors.

Journal: Histopathology

Published: September 10, 2017

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.

Journal: Journal of the National Cancer Institute

Published: October 26, 2016

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).

Journal: ESMO open

Published: October 07, 2016

Regorafenib induced severe toxic hepatitis: characterization and discussion.

Regorafenib induced severe toxic hepatitis: characterization and discussion.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: March 16, 2016

Ossification of a rectal tumor: an uncommon finding.

Ossification of a rectal tumor: an uncommon finding.

Journal: Acta gastro-enterologica Belgica

Published: December 30, 2015

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.

Journal: Targeted oncology

Published: December 27, 2015

Lymph node ratio and surgical quality are strong prognostic factors of rectal cancer: results from a single referral centre.

Lymph node ratio and surgical quality are strong prognostic factors of rectal cancer: results from a single referral centre.

Journal: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland

Published: August 27, 2015

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).

Journal: PloS one

Published: May 06, 2015

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 28, 2015

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Journal: The Lancet. Oncology

Published: March 05, 2015

Showing 1-12 of 24

Last Updated: 09/26/2026